Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1951 1
1953 1
1954 2
1956 2
1958 2
1959 4
1960 4
1961 4
1962 3
1963 6
1964 10
1965 5
1966 12
1967 4
1968 5
1969 6
1970 11
1971 7
1972 9
1973 7
1974 12
1975 12
1976 7
1977 8
1978 5
1979 9
1980 7
1981 3
1982 4
1984 4
1985 4
1986 5
1987 3
1988 4
1989 2
1990 3
1991 2
1992 5
1994 9
1995 8
1996 3
1997 6
1998 7
1999 5
2000 4
2001 5
2002 3
2003 3
2004 2
2005 10
2006 9
2007 6
2008 13
2009 12
2010 18
2011 20
2012 19
2013 8
2014 2
2015 8
2016 6
2017 6
2018 5
2019 11
2020 11
2021 14
2022 13
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

437 results

Results by year

Filters applied: . Clear all
Page 1
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Joshua AM, Sacco JJ, Shoushtari AN, Orloff M, Piulats JM, Milhem M, Salama AKS, Curti B, Demidov L, Gastaud L, Mauch C, Yushak M, Carvajal RD, Hamid O, Abdullah SE, Holland C, Goodall H, Piperno-Neumann S; IMCgp100-202 Investigators. Nathan P, et al. Among authors: orloff m. N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485. N Engl J Med. 2021. PMID: 34551229 Free article. Clinical Trial.
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A. Chesney J, et al. Among authors: orloff m. J Immunother Cancer. 2022 Dec;10(12):e005755. doi: 10.1136/jitc-2022-005755. J Immunother Cancer. 2022. PMID: 36600653 Free PMC article. Clinical Trial.
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, Sullivan RJ, Dummer R, Kirkwood JM, Orloff M, Sacco JJ, Ochsenreither S, Joshua AM, Gastaud L, Curti B, Piulats JM, Salama AKS, Shoushtari AN, Demidov L, Milhem M, Chmielowski B, Kim KB, Carvajal RD, Hamid O, Collins L, Ranade K, Holland C, Pfeiffer C, Nathan P. Hassel JC, et al. Among authors: orloff m. N Engl J Med. 2023 Dec 14;389(24):2256-2266. doi: 10.1056/NEJMoa2304753. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870955 Clinical Trial.
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
Carvajal RD, Nathan P, Sacco JJ, Orloff M, Hernandez-Aya LF, Yang J, Luke JJ, Butler MO, Stanhope S, Collins L, McAlpine C, Holland C, Abdullah SE, Sato T. Carvajal RD, et al. Among authors: orloff m. J Clin Oncol. 2022 Jun 10;40(17):1939-1948. doi: 10.1200/JCO.21.01805. Epub 2022 Mar 7. J Clin Oncol. 2022. PMID: 35254876 Free PMC article. Clinical Trial.
Melanoma Immunotherapy in the Elderly.
Orloff M. Orloff M. Curr Oncol Rep. 2018 Mar 2;20(2):20. doi: 10.1007/s11912-018-0656-3. Curr Oncol Rep. 2018. PMID: 29500787 Review.
Treatment of Metastatic Melanoma in the Elderly.
Seedor RS, Orloff M. Seedor RS, et al. Among authors: orloff m. Curr Oncol Rep. 2022 Jul;24(7):825-833. doi: 10.1007/s11912-022-01257-5. Epub 2022 Mar 22. Curr Oncol Rep. 2022. PMID: 35316844 Review.
Review of bi-specific therapies in uveal melanoma.
Orloff M, Seedor R, Sato T. Orloff M, et al. Cancer Gene Ther. 2022 Dec;29(12):1814-1818. doi: 10.1038/s41417-022-00442-9. Epub 2022 Mar 2. Cancer Gene Ther. 2022. PMID: 35236927 Review.
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
Hamid O, Hassel JC, Shoushtari AN, Meier F, Bauer TM, Salama AKS, Kirkwood JM, Ascierto PA, Lorigan PC, Mauch C, Orloff M, Evans TRJ, Holland C, Edukulla R, Abedin SE, Middleton MR. Hamid O, et al. Among authors: orloff m. J Immunother Cancer. 2023 Jun;11(6):e006747. doi: 10.1136/jitc-2023-006747. J Immunother Cancer. 2023. PMID: 37286303 Free PMC article. Clinical Trial.
437 results